{
    "Trade/Device Name(s)": [
        "CellSearch\u2122 Circulating Tumor Cell Kit"
    ],
    "Submitter Information": "Veridex, LLC",
    "510(k) Number": "K071729",
    "Predicate Device Reference 510(k) Number(s)": [
        "K062013"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NQI"
    ],
    "Summary Letter Date": "November 20, 2007",
    "Summary Letter Received Date": "October 30, 2007",
    "Submission Date": "October 29, 2007",
    "Regulation Number(s)": [
        "21 CFR 866.6020"
    ],
    "Regulation Name(s)": [
        "Immunomagnetic circulating cancer cell selection and enumeration system"
    ],
    "Analyte Class(es)": [
        "cancer molecular",
        "immunology"
    ],
    "Analyte(s)": [
        "Circulating tumor cells of epithelial origin (CD45-, EpCAM+, cytokeratins 8+, 18+, 19+)"
    ],
    "Specimen Type(s)": [
        "Whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "CellTracks\u00ae AutoPrep\u00ae System",
        "MagNest\u00ae device",
        "CellTracks\u00ae Analyzer II",
        "CellTracks\u00ae Analyzer I",
        "CellSpotter\u00ae Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Immunomagnetic cell capture",
        "Immunofluorescence labeling"
    ],
    "Methodologies": [
        "Enumeration of circulating tumor cells",
        "Automated imaging and cell classification"
    ],
    "Submission Type(s)": [
        "Kit",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Veridex CellSearch Circulating Tumor Cell Kit for enumerating circulating tumor cells in whole blood of metastatic breast and colorectal cancer patients",
    "Indications for Use Summary": "Intended for enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, cytokeratins 8+, 18+, and/or 19+) in whole blood; presence of CTC is associated with decreased progression free and overall survival in patients with metastatic breast or colorectal cancer, to aid in monitoring these patients in conjunction with other clinical methods.",
    "fda_folder": "Immunology"
}